|
Pelabresib Clinical Trials
2 actively recruiting trials across 1 location
▲ +1 trial since May 2026
Also known as: CPI-0610, DAK539 (formerly CPI-0610)
Pipeline
Phase 1: 1Phase 3: 1
Top Sponsors
- Novartis Pharmaceuticals2
Indications
- Cancer2
- Advanced Malignancies and Hepatic Impairment1
- Advanced Malignancies1
- Hematologic Malignancy1
- Solid Tumor1
Other1 trial
Los Angeles, California1 trial
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology)
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.